ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS
申请人:Pinto Donald J.P.
公开号:US20100016316A1
公开(公告)日:2010-01-21
The present invention provides compounds of Formula (I) or (II):
or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L
1
, R
3
, R
4
, R
8a
, R
11
and M are as defined herein. The compounds of Formula (I) or (II) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
本发明提供了化合物的结构式(I)或(II):
或其立体异构体、互变异构体、药学上可接受的盐或溶剂形式,其中变量A、L1、R3、R4、R8a、R11和M如本文所定义。结构式(I)或(II)的化合物是凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂;例如凝血酶、Xa因子、XIa因子、IXa因子、VIIa因子和/或血浆激肽。具体而言,涉及选择性XIa因子抑制剂或fXIa和血浆激肽的双重抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。